Arcus Biosciences Q3 EPS $(1.27) Beats $(1.33) Estimate, Sales $26.000M Beat $21.400M Estimate

Author: Benzinga Newsdesk | October 28, 2025 03:39pm
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.33) by 4.3 percent. This is a 27 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $26.000 million which beat the analyst consensus estimate of $21.400 million by 21.50 percent. This is a 45.83 percent decrease over sales of $48.000 million the same period last year.

Posted In: RCUS